The distribution of COVID-19 vaccine that requires only one dose began recently in Shanghai.

The recombinant novel coronavirus vaccine developed by CanSino Biologics which requires only one dose has applied different production technologies in comparison to the previous three kinds of inactivated vaccine distributed in Shanghai, as these vaccines share the same injection techniques and vaccination age groups.

The results of clinical trials, emergency use and post market surveillance show both the recombinant novel coronavirus vaccine and the inactivated vaccines have a good safety profile.

The number of required doses may vary due to different production processes based on research and technological development of different kinds of vaccines, according to the municipal disease prevention and control center. (Photos: Xinhua; Compiled by Xia Fan)